Jan 28, 2022

Medscape has launched a new enduring activity designed to enhance clinicians’ awareness of gene therapy for hemophilia and increase their confidence when it comes to the eventual integration of these paradigm-shifting therapeutics into the clinical care of patients.

The program, which was developed through a partnership between Medscape and NHF, is intended for an international audience of hematologists/oncologists, pediatricians, hematology/oncology nurses, nurse practitioners, and physician assistants.

Participants who complete the activity will:

  • Have increased knowledge regarding the
    • Safety data associated with gene therapy technologies for hemophilia
  • Have greater competence related to
    • Identifying patients who may be candidates for gene therapy
  • Demonstrate greater confidence in their ability to
    • Identify multidisciplinary strategies for optimizing gene therapy integration into the clinical care of patients with hemophilia

Accreditation Information
Authors: David Lillicrap, MD
CME / ABIM MOC Released: 1/19/2022
Valid for credit through: 1/19/2023
*Follow the link below to for more details about receiving credits for this CME activity.

If you are already registered with Medscape follow this link to “Gene Therapy and Hemophilia Care Updates: Bringing Your Treatment Center up to Speed.”

If you are not already registered, go to Medscape.org to register at no cost.

This program is supported by independent educational grants from Spark Therapeutics, Pfizer, and BioMarin.